Mimedx achieved record net sales of $114 million in Q3 2025, a 35% increase year-over-year, with significant growth in both its Wound and Surgical product categories. The company also reported strong GAAP net income of $17 million and adjusted EBITDA of $35 million, representing a 31% margin, and raised its full-year 2025 net sales growth and adjusted EBITDA expectations.

Mimedx achieved its highest quarterly net sales in company history, reaching $99 million, driven by double-digit growth in both Wound and Surgical product categories. The company also reported a record Adjusted EBITDA of $24 million, reflecting strong operational efficiency and expense discipline. GAAP net income and diluted EPS were $10 million and $0.06, respectively.

MIMEDX delivered a solid first quarter for 2025 with 4% year-over-year net sales growth driven by strong performance in surgical products. While facing setbacks with LCDs, the company is strategically adding new products to navigate the reimbursement landscape and remains focused on expanding the use cases for its proprietary technology.

MiMedx Group, Inc. reported strong fourth quarter and full year 2024 results, with net sales growing 7% year-over-year for the quarter to $93 million and Adjusted EBITDA margin at 21% of net sales. The company also generated strong free cash flow, despite challenges in Medicare reimbursement.

MiMedx announced solid third quarter 2024 results with total net sales growth of 3% year-over-year and an Adjusted EBITDA margin of 22%. The company is optimistic about addressing Medicare spending and remains committed to research and evidence production.

MiMedx reported a 7% increase in net sales, reaching $87 million for the second quarter of 2024. The company's GAAP net income was $18 million, with an Adjusted EBITDA of $20 million, representing 23% of net sales. The growth was driven by AMNIOEFFECT® and EPIEFFECT® products, despite competitive challenges.

MiMedx Group, Inc. announced strong first quarter 2024 results, with net sales of $85 million, representing an 18% increase year-over-year. The company reported GAAP net income of $9 million and an Adjusted EBITDA of $19 million, or 22% of net sales. They also expanded their portfolio with a distribution agreement for a new xenograft product.

MiMedx Group, Inc. announced strong operating and financial results for the fourth quarter and full year 2023. The company reported a 17% increase in net sales for the fourth quarter, reaching $87 million. Net income for the quarter was $53 million, and adjusted EBITDA was $21 million, representing 24% of net sales.

MiMedx announced strong Q3 2023 results, with net sales increasing by 20.7% year-over-year to $81.7 million and GAAP net income of $8.5 million. The company's Adjusted EBITDA was $17.6 million, representing 21.6% of net sales. MIMEDX raised its full-year 2023 net sales percentage growth outlook to the high teens.

MiMedx Group, Inc. announced strong second quarter 2023 results, with net sales of $81.3 million and a net income of $1.2 million. The company's top-line growth was 21.5% compared to the prior year. They are increasing full-year 2023 net sales growth guidance to the mid to high teens.

MiMedx Group, Inc. announced its Q1 2023 results, featuring a 21.7% increase in net sales to $71.7 million compared to the prior year period. The company reported a net loss of $5.0 million and an Adjusted EBITDA of $5.5 million, driven by demand for new products and improved cost controls.

MiMedx Group, Inc. reported a 10.3% increase in net sales for the fourth quarter of 2022, reaching $74.4 million compared to $67.4 million in the prior year period. The company's net loss for the quarter was $0.4 million, compared to a net income of $2.2 million for the same period in 2021.

Mimedx Group, Inc. reported a 7.3% increase in net sales for the third quarter of 2022, reaching $67.7 million. The growth was driven by demand for surgical recovery products, including new products AMNIOEFFECT and AXIOFILL. The company's net loss for the quarter was $8.4 million, compared to a net loss of $2.3 million for the prior year period.

MiMedx Group, Inc. reported second quarter net sales of $66.9 million, reflecting double-digit revenue increase for the fourth consecutive quarter in the Company's continuing portfolio of products. The company achieved strong year-over-year revenue growth in key focus area of Surgical Recovery and reaffirms 2022 revenue growth outlook of 11% to 14% in continuing portfolio of products.

MiMedx Group, Inc. announced its first quarter 2022 results, with net sales of $58.9 million, a slight decrease compared to the prior year. However, the continuing portfolio of tissue and cord products experienced a 13% increase in revenue. The company reported a net loss of $10.5 million for the quarter.

MiMedx Group, Inc. reported Q4 2021 net sales of $67.4 million and a net income of $2.2 million. The company's Advanced Wound Care products saw a 13% increase in sales, driven by growth in the AMNIOFIX® sheet portfolio and the EPICORD® Expandable product line. Looking ahead, MiMedx is well-poised for continued growth, with plans for the EPIFIX launch in Japan and new product innovations in the U.S.

MiMedx Group, Inc. reported net sales of $60.0 million for Q1 2021, a slight decrease compared to $61.7 million in the prior year. The company is progressing with its late-stage clinical programs and expanding its field personnel.

MiMedx reported Q4 net sales of $68.5 million and a net loss of $16.6 million. The company's adjusted EBITDA was $10.3 million. Full year net sales were $248.2 million with a net loss of $49.3 million.

MiMedx reported Q3 2020 net sales of $64.3 million. The company achieved several key objectives, including a strong rebound in sequential sales growth, the launch of EpiCord® Expandable, and the relisting of shares on Nasdaq.